Emilia Romagna

Farmeconomia: Health Economics and Therapeutic Pathways

Simone Gerzeli¹  Nadia Demarteau²  Filippo Cipriani³  Alessia Marocco³  Francesco Bamfi³  Maria Caterina Cavallo⁴ 

[1] Dipartimento di Statistica ed Economia Applicate L. Lenti, Università di Pavia;GlaxoSmithKline Biologicals, Wavre (Belgio);GlaxoSmithKline Spa, Verona;Università Bocconi, Milano;

关键词: emilia romagna;    hpv vaccination;    economic & clinical impact;   

DOI  :  10.7175/fe.v9i1S.1007

来源: DOAJ

【 摘 要 】

In Emilia Romagna region 77,6% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 51 cases of cervicocarcinoma and 22 related deaths and thus results to be cost-effective (29.903€/QALY). When the vaccination programme is extended to 16-year-old girls a further 47 cancer cases and 20 deaths could be prevented, with a very similar cost-effectiveness ratio. In Emilia Romagna region, the net cost for woman vaccinated is 177€ for the single cohort and 180€ for the multiple cohort.

【 授权许可】

Unknown